Eyepoint's Phase 3 Trial for Age-Related Blindness Treatment Misses Primary Endpoint
Source Summary
Eyepoint disclosed that a Phase 3 trial of its experimental treatment for a common cause of age-related blindness failed to meet its primary goal.
Eyepoint disclosed that a Phase 3 trial of its experimental treatment for a common cause of age-related blindness failed to meet its primary goal.
